PropertyValue
?:abstract
  • Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the liver is an organ likely to participate in the viral response against SARS-CoV-2 and this may predispose it to injury. A better understanding of the mechanism contributing to liver injury is needed to develop and implement early measures to prevent serious liver damage in patients suffering from COVID-19. This review summarizes current reports of SARS-CoV-2 with an emphasis on how direct infection and subsequent severe inflammatory response may contribute to liver injury in patients with and without preexisting liver disease.
?:creator
?:doi
  • 10.1055/s-0040-1715108
?:doi
?:journal
  • Seminars_in_liver_disease
?:license
  • unk
?:pmid
?:pmid
  • 32886936.0
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients.
?:type
?:year
  • 2020-08-01

Metadata

Anon_0  
expand all